New England Journal of Medicine· 2019Q1

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML

Alexander E. Perl, Giovanni Martinelli, Jörge E. Cortes, Andreas Neubauer et al.

1,254citations
Q1SCImago
2019year

Short summary

Gilteritinib significantly improved overall survival (9.3 vs. 5.6 months) and complete remission rates (34.0% vs. 15.3%) compared to salvage chemotherapy in patients with relapsed or refractory FLT3-mutated AML.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Hematology

HematologyMedicine